It's approved to reduce risk of cardiovascular death and hospitalization for heart failure in adults
Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice
Targeting No
20 In SOUL, a randomized, placebo-controlled trial examining the effects of the oral GLP-1 RA semaglutide on the risk of cardiovascular events in 9650 individuals with T2D and established ASCVD and/or CKD, use of SGLT2i at baseline was 26.9%, providing the largest data set from a single CVOT on the combined use of GLP-1 RA and SGLT2i
The best peptide option depends on your symptoms, health history, current medications, treatment goals, and provider assessment
A pivotal shift occurred on December 1, 2025, when the World Health Organization (WHO) released its first-ever clinical guidelines recommending GLP-1 receptor agonists for the long-term treatment of obesity